XML 60 R47.htm IDEA: XBRL DOCUMENT
v3.20.2

Identifiable Intangible Assets - Additional Information (Detail) $ in Millions | 3 Months Ended | 9 Months Ended
--- | --- | ---
Sep. 30, 2020 USD ($) | Sep. 30, 2019 USD ($) | Sep. 30, 2020 USD ($) | Sep. 30, 2019 USD ($)
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Amortization of intangible assets useful life |  |  | 12 years |
Amortization of intangible assets | $ 251 | $ 255 | $ 758 | $ 823
Impairment of intangible assets excluding goodwill | 509 | 177 | 1,278 | 1,206
In Process Research and Development [Member] |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Impairment of intangible assets excluding goodwill | $ 360 |  | $ 708 | 539
Business combination, contingent consideration, liability, measurement input | 0.80 |  | 0.80 |
In Process Research and Development [Member] | Minimum [Member] |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Business combination, contingent consideration, liability, measurement input | 0.075 |  | 0.075 |
In Process Research and Development [Member] | Maximum [Member] |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Business combination, contingent consideration, liability, measurement input | 0.09 |  | 0.09 |
In Process Research and Development [Member] | Lenalidomide Product [Member] |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Impairment of intangible assets excluding goodwill | $ 262 |  | $ 262 | 125
Identifiable product rights [Member] | Market assumptions regarding price and volume of products [Member] |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Impairment of intangible assets excluding goodwill | 39 |  |  |
Identifiable product rights [Member] | Metformin tablets product [Member] |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Impairment of intangible assets excluding goodwill | 110 |  | 110 |
Actavis [Member] | In Process Research and Development [Member] |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Business combination recognized identifiable assets | 964 |  | 964 |
Impairment of intangible assets excluding goodwill |  |  |  | 59
Actavis [Member] | In Process Research and Development [Member] | Generic Pipeline Products [Member] |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Impairment of intangible assets excluding goodwill | 96 | 78 | 213 | 355
Actavis [Member] | Identifiable product rights [Member] |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Impairment of intangible assets excluding goodwill | $ 149 | $ 99 | 570 | $ 667
AUSTEDO [Member] | In Process Research and Development [Member] |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Impairment of intangible assets excluding goodwill |  |  | 211 |
Japan [Member] | Actavis [Member] | In Process Research and Development [Member] |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Impairment of intangible assets excluding goodwill |  |  | 165 |
United States [Member] | Actavis [Member] | In Process Research and Development [Member] |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Impairment of intangible assets excluding goodwill |  |  | $ 271 |

X
- Definition The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(2) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274 + Details
Name: | us-gaap_AmortizationOfIntangibleAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Value of input used to measure contingent consideration liability from business combination. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput
Namespace Prefix: | us-gaap_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of assets acquired at the acquisition date. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472 + Details
Name: | us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetUsefulLife
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 3 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275 + Details
Name: | us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=teva_LenalidomideProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=teva_ProductRightsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentAxis=teva_MarketAssumptionsRegardingPriceAndVolumeOfProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=teva_MetforminTabletsProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=teva_ActavisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=teva_GenericPipelineProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=teva_AustedoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_JP
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |